Impact on Quality of Life and Burden of Disease in Adults With Herpes Zoster

Launched by INSTITUTO DE INVESTIGACIÓN SANITARIA DE LA FUNDACIÓN JIMÉNEZ DÍAZ · Oct 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how herpes zoster, also known as shingles, affects the quality of life of adults. The goal is to understand the burden of this disease and how immunization can help. This trial will involve two groups of participants: one group will be people over 18 years old who are getting vaccinated against shingles, and the other group will include adults who were diagnosed with shingles from 2012 to 2023.

To participate in the study, individuals must be over 18 years old and not pregnant. People with certain conditions that might prevent them from answering questions, like severe dementia, will not be included. Participants can expect to provide information about their experiences with shingles, including how it has impacted their daily lives. This study is important because it aims to gather valuable information that could improve the understanding and treatment of shingles, helping to reduce its impact on patients.

Gender

ALL

Eligibility criteria

• • 1 Prospective cohort study Inclusion criteria Patients \> 18 years of age who are to be immunized against HZ
• Exclusion criteria:
• • Pregnant women
• • Patients with altered level of consciousness (dementia and others) who do not complete the questionnaires
• • Patients who do not wish to participate in the study 5.2 Retrospective cohort study Inclusion criteria Adults \>18 years of age with a diagnosis of HZ in the CMBD from 2012 to 2023 at the Jiménez Díaz Foundation hospital. Since the international classification of diseases changed from ICD 9 to ICD 10 in 2106, the codes to be used for the inclusion of patients in the study are described below.
• • ICD 9 053 Herpes zoster
• Includes:
• • Herpes zoster
• • Zone 053.0 With meningitis 053.1 With other central nervous system complications
• • 053.10 With unspecified nervous system complications
• • 053.11 Geniculate herpes zoster or Herpetic geniculate ganglionitis
• • 053.12 Postherpetic trigeminal neuralgia
• • 053.13 Postherpetic polyneuropathy
• • 053.14 Herpes zoster myelitis
• • 053.19 Other 053.2 With ophthalmic complications
• • 053.20 Herpes zoster dermatitis of eyelid or Herpes zoster ophthalmicus
• • 053.21 Herpes zoster keratoconjunctivitis
• • 053.22 Herpes zoster iridocyclitis zoster
• • 053.29 Other 053.7 With other specific complications
• • 053.71 Otitis externa due to herpes zoster
• • 053.79 Other 053.8 With unspecified complications 053.9 Herpes zoster without complication Herpes zoster NOS ICD 10 B02 Herpes zoster
• Includes:
• • herpes
• • zona B02.0 Encephalitis due to herpes zoster Meningoencephalitis due to zoster B02.1 Meningitis due to herpes zoster B02.2 Herpes zoster with other nervous system involvement
• • B02.21 Postherpetic geniculate ganglionitis
• • B02.22 Postherpetic trigeminal neuralgia
• • B02.23 Postherpetic polyneuropathy
• • B.02.24 Myelitis Postherpetic myelitis
• • B02.29 Other postherpetic nervous system involvement
• • B02.3 Ocular herpes zoster
• • B02.30 Ocular herpes zoster, unspecified
• • B02.31 Herpes zoster conjunctivitis
• • B02.32 Herpes zoster iridocyclitis
• • B02.33 Herpes zoster keratitis
• • B02.34 Herpes zoster scleritis
• • B02.39 Other herpes zoster eye disease
• • B02.7 Disseminated herpes zoster
• • B02.8 Herpes zoster with other complications
• • B02.9 Uncomplicated herpes zoster
• • B02.39 Herpes zoster otitis externa NEOM
• Exclusion criteria:
• • Patients who are vaccinated against HZV